Clinical and molecular surveillance of artemisinin resistant falciparum malaria in Myanmar (2009–2013)

Malaria Journal

Table 3 Association between single nucleotide polymorphism in target genes and day 3 parasite positivity after artemisinin combination therapy

Target gene	SNP(s)	Odd ratio	95% CI	P
k13	K13^a	6.4810	3.4095–12.3197	<0.0001
pfarps10	V127M	3.8841	1.9900–7.5808	<0.0001
pffd	D193Y	2.8784	1.4456–5.7312	0.0018
pfmdr2	T484I	2.5181	1.3619–4.6559	0.0025
k13 + pfarps10	K13 + V127M	5.3470	2.919–9.7948	<0.0001
k13 + pffd	K13 + D193Y	4.9164	2.7202–8.8855	<0.0001
k13 + pfmdr2	K13 + T484I	4.4647	2.4812–8.0341	<0.0001
pfarps10 + pffd	V127M + D193Y	3.2796	1.8004–5.9742	0.0001
pfarps10 + pfmdr2	V127 +T484I	2.5541	1.4344–4.5478	0.0011
pffd + pfmdr2	D193Y + T484I	1.9758	1.1105–3.5152	0.0188
k13 + pfarps10 + pfmdr2	K13 + V127M + T484I	4.2245	2.3335–7.6479	<0.0001
k13 + pffd + pfmdr2	K13 + D193Y + T484I	3.4875	1.9084–6.3731	<0.0001
k13 + pfarps10 + pffd	K13 + V127M + D193Y	4.8354	2.6840–8.7113	<0.0001
pfarps10 + pffd + pfmdr2	V127M + D193Y + T484I	2.2926	1.2798–4.1069	0.0044
k13 + pfarps10 + pffd + pfmdr2	K13 + V127 M + D193Y + T484I	3.7588	2.0371–6.9356	<0.0001

SNP single nucleotide polymorphism, CI confidence interval, ACT artemisinin-based combination therapy
^aFor K13, any non-synonymous mutation in kelch propeller domain, after amino acid position 440 was analysed

ISSN: 1475-2875